Sovateltide

Sovateltide

Sovateltide

Chemical compound


Sovateltide (development names IRL-1620 and PMZ-1620,[1] sold in India under the brand name Tyvalzi)[2] is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz.[2] Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis).[3][4] Sovateltide also protects neural mitochondria and enhances their biogenesis.[5]

Quick Facts Clinical data, Trade names ...

References

  1. Gulati, Anil; Agrawal, Nilesh; Vibha, Deepti; Misra, U. K.; Paul, Birinder; Jain, Dinesh; Pandian, Jeyaraj; Borgohain, Rupam (January 2021). "Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke". CNS Drugs. 35 (1): 85–104. doi:10.1007/s40263-020-00783-9. ISSN 1179-1934. PMC 7872992. PMID 33428177.
  2. Keam, Susan J. (September 2023). "Sovateltide: First Approval". Drugs. 83 (13): 1239–1244. doi:10.1007/s40265-023-01922-4. ISSN 1179-1950. PMID 37486545. S2CID 260114948.
  3. Ranjan, Amaresh K.; Gulati, Anil (2022-03-15). "Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders". International Journal of Molecular Sciences. 23 (6): 3146. doi:10.3390/ijms23063146. ISSN 1422-0067. PMC 8955091. PMID 35328566.
  4. Ranjan, Amaresh K.; Briyal, Seema; Khandekar, Divya; Gulati, Anil (September 2020). "Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke". Canadian Journal of Physiology and Pharmacology. 98 (9): 659–666. doi:10.1139/cjpp-2020-0164. ISSN 0008-4212. PMID 32574518.

Share this article:

This article uses material from the Wikipedia article Sovateltide, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.